Media coverage about Adaptimmune Therapeutics (NASDAQ:ADAP) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adaptimmune Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.5529278821598 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
ADAP has been the subject of a number of research analyst reports. SunTrust Banks reaffirmed a “buy” rating and issued a $10.00 target price on shares of Adaptimmune Therapeutics in a research note on Friday, November 10th. TheStreet raised shares of Adaptimmune Therapeutics from a “d” rating to a “c” rating in a research note on Thursday, November 2nd. Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. BidaskClub lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Finally, ValuEngine lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $11.58.
Adaptimmune Therapeutics (NASDAQ ADAP) opened at $8.32 on Tuesday. The firm has a market cap of $779.47 and a price-to-earnings ratio of -11.09. Adaptimmune Therapeutics has a one year low of $3.88 and a one year high of $9.70.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.